This company has been acquiredThe company may no longer be operating, as it has been acquired. Find out why through their latest events.See Latest EventsReunion Neuroscience（REUN）株式概要Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company, develops therapeutic solutions for mental health conditions in North America. 詳細REUN ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性4/6配当金0/6リスク分析収益が 100 万ドル未満 ( CA$0 )US市場と比較して、過去 3 か月間の株価の変動が非常に大きいキャッシュランウェイが1年未満である 意味のある時価総額がありません ( $12M )すべてのリスクチェックを見るREUN Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW478,741 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA478,741 investors already sharing narrativesYour Fair ValueUS$Current PriceUS$1.12該当なし内在価値ディスカウントEst. Revenue$PastFuture-38m961k2016201920222025202620282031Revenue CA$1.0Earnings CA$0.2AdvancedSet Fair ValueView all narrativesReunion Neuroscience Inc. 競合他社CytoMed TherapeuticsSymbol: NasdaqCM:GDTCMarket cap: US$11.5mPalatin TechnologiesSymbol: NasdaqCM:PTNMarket cap: US$17.1mFresh Tracks TherapeuticsSymbol: OTCPK:FRTXMarket cap: US$5.6mBolt BiotherapeuticsSymbol: NasdaqCM:BOLTMarket cap: US$7.7m価格と性能株価の高値、安値、推移の概要Reunion Neuroscience過去の株価現在の株価CA$1.1252週高値CA$7.6252週安値CA$0.63ベータ4.211ヶ月の変化0.90%3ヶ月変化45.47%1年変化-72.96%3年間の変化n/a5年間の変化n/aIPOからの変化-89.05%最新ニュースお知らせ • Jul 23Reunion Neuroscience Inc. Announces First Patient Dosed in Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum DepressionReunion Neuroscience Inc. announced that the first patient has been dosed in the RECONNECT Phase 2 clinical trial of RE104 for the treatment of postpartum depression (PPD). RE104 was designed to be a safe, fast-acting, single-dose therapy to benefit patients suffering from underserved mental health disorders, including PPD. The RECONNECT Phase 2 clinical trial (NCT06342310) is a multicenter, randomized, double-blind, parallel-group, active dose-controlled clinical trial evaluating the safety and efficacy of a single subcutaneous dose of RE104 in adult female patients with moderate-to-severe PPD. The primary endpoint of the trial is the change in total Montgomery-Åsberg Depression Rating Scale (MADRS) score, a 10-item clinician rated scale measuring depression severity from baseline, at Day 7. Key secondary endpoints include the change in total MADRS score from baseline at Day 1, 14 and 28, MADRS response indicating a = 50% reduction in symptoms, MADRS remission with a score of = 10, as well as safety and tolerability. The Company’s lead product candidate, RE104, is a proprietary, potential best-in-class, patented prodrug of 4-OH-DiPT. Reunion designed RE104 to deliver a short duration psychedelic experience compared to longer duration psychedelics like psilocybin. In a Phase 1 clinical trial, RE104 produced a psychedelic state similar in intensity and quality to psilocybin, but lasting only about half the time (3-4 hours), while demonstrating a similar, favorable safety profile. RE104 is currently being evaluated in the RECONNECT Phase 2 (NCT06342310) clinical trial, a multicenter, randomized, double-blind, active dose-controlled clinical trial in moderate-to-severe Postpartum Depression (PPD) patients. Reunion is actively evaluating the use of RE104 in additional neuropsychiatric indications, including adjustment disorder in cancer patients, where there remains a significant unmet need that is not addressed by the current standard of care. Postpartum depression (PPD) is one of the most common medical complications during and after pregnancy and is estimated to affect approximately 10-15% of all mothers of newborns. PPD is a form of major depression that can severely impact women and their families. According to the Centers for Disease Control and Prevention, the leading underlying cause of pregnancy-related death during the first postpartum year are due to mental health conditions, with suicide being the leading manner of death. Women suffering from PPD often experience significant changes in mood, appetite and sleep contributing to feelings of hopelessness, lack of concentration, loss of energy, poor self-esteem and maternal disinterest.お知らせ • May 03+ 1 more updateReunion Neuroscience Inc. announced that it has received CAD 103 million in funding from a group of investorsOn May 2, 2024, Reunion Neuroscience Inc. closed the transaction. The company has received $94,500,000 in its second and final tranche, bringing the total funds raised to $103,000,000 in the transaction. The transaction was co-led by new investors, MPM Asset Management, L.L.C. and Novo Holdings A/S and also included participation from new investors, Arkin Bio-Capital, a fund managed by Arkin Holdings, Mitsui & Co. Global Investment, Inc., Plaisance Capital LLC, FemHealth Ventures LLC, Palo Santo as well as a syndicate composed of top-tier institutional healthcare investors.お知らせ • Sep 20Reunion Neuroscience Inc. Announces FDA Clearance of IND Application to Initiate A Phase 2 Study of Re104 for the Treatment of Postpartum DepressionReunion Neuroscience Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to initiate a Phase 2 study of RE104, a novel serotonergic psychedelic compound, for the treatment of postpartum depression (PPD). The Phase 2 study, the RECONNECT Trial, is a multicenter, randomized, double-blind, parallel-group, active-dose placebo-controlled study, which will evaluate the safety and efficacy of a single subcutaneous dose of RE104 in adult female patients with PPD. The study is expected to begin in fourth quarter 2023 with a targeted data readout in late 2024.お知らせ • Aug 19Reunion Neuroscience Inc. Files Form 15Reunion Neuroscience Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Shares under the Securities Exchange Act of 1934, as amended.お知らせ • Aug 03+ 1 more updateMPM Asset Management, L.L.C. acquired Reunion Neuroscience Inc. (TSX:REUN) in a going private transaction.MPM Asset Management, L.L.C. entered into a definitive arrangement agreement to acquire Reunion Neuroscience Inc. (TSX:REUN) for CAD 17.8 million in a going private transaction on May 31, 2023. MPM would acquire Reunion in an all-cash transaction valued at approximately $13.1 million (CAD 17,809,536). Pursuant to the terms and conditions, Reunion shareholders shall receive CAD 1.52 per share. Post deal completion, Reunion will no longer be traded or listed on any public securities exchange and will be wholly-owned by affiliates of MPM. Reunion's board of directors has unanimously approved the transaction. In case of termination of the transaction under certain circumstances, Reunion Neuroscience will be required to pay a termination fee of $0.8 million (CAD 1,067,000). Completion of the Arrangement remains subject to the approval of the Shareholders at the Meeting, obtaining all applicable regulatory approvals, including approval of the Ontario Superior Court of Justice (Commercial List) (the "Court") of the Arrangement and the net cash held by the Company being equal to or greater than $8 million (CAD 10,876,052) as of the close of business. Shareholders meeting is scheduled on July 12, 2023. On July 12, 2023 at the Meeting, shareholders voted in favor of a special resolution to approve the proposed plan of arrangement under Section 192 of the Canada Business Corporations Act. As of July 14, 2023, the transaction has received the final Ontario Superior Court of Justice approval. The deal is expected to close in the calendar third quarter of 2023. As of July 14, 2023, the transaction is expected to close on or about July 21, 2023.Oppenheimer & Co. Inc. is serving as exclusive financial advisor to the Special Committee of the Board of Directors of Reunion and PI Financial Corp. rendered a fairness opinion to Reunion, and Aaron Sonshine and Kris Hanc of Bennett Jones LLP and Steven M. Cohen, Veronica DiCamillo and Jacqueline Berman of Morgan, Lewis & Bockius LLP are serving as legal advisors. Jonathan See and Rami Chalabi of McCarthy Tétrault LLP and Wilmer Cutler Pickering Hale and Dorr LLP are serving as legal advisors to MPM. Computershare Investor Services Inc. is the depository bank for Reunion.MPM Asset Management, L.L.C. acquired Reunion Neuroscience Inc. (TSX:REUN) in a going private transaction on August 1, 2023. With the completion of the Arrangement, the Shares are expected to be de-listed from the Toronto Stock Exchange on the close of markets on or around August 2, 2023. The Company is in the process of applying to cease to be a reporting issuer under applicable Canadian securities laws. The Shares will be delisted from the Nasdaq Global Select Market and deregistered under the Securities Exchange Act of 1934, as amended.お知らせ • Aug 02Reunion Neuroscience's Shares to Be De-Listed from the Toronto Stock Exchange on the Close of Markets on or Around August 2, 2023Reunion Neuroscience Inc. and MPM BioImpact ("MPM") announced the completion of the previously announced plan of arrangement (the "Arrangement") effective August 1, 2023, whereby MPM acquired Reunion in an all-cash transaction valued at approximately USD 13.1 million by way of a court-approved plan of arrangement under Section 192 of the Canada Business Corporations Act. Pursuant to the terms and conditions of a definitive arrangement agreement entered into by Reunion and affiliates of MPM on May 31, 2023, all holders of outstanding common shares ("Shares") of Reunion are entitled to receive USD 1.12 in cash for each Share held immediately prior to the effective time of the Arrangement. As previously announced, the Arrangement was approved by shareholders of the Company at its special meeting of shareholders held on July 12, 2023 and by the Ontario Superior Court of Justice (Commercial List) on July 14, 2023. With the completion of the Arrangement, the Shares are expected to be de-listed from the Toronto Stock Exchange on the close of markets on or around August 2, 2023. The Company is in the process of applying to cease to be a reporting issuer under applicable Canadian securities laws. The Shares will be delisted from the Nasdaq Global Select Market and deregistered under the Securities Exchange Act of 1934, as amended.最新情報をもっと見るRecent updatesお知らせ • Jul 23Reunion Neuroscience Inc. Announces First Patient Dosed in Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum DepressionReunion Neuroscience Inc. announced that the first patient has been dosed in the RECONNECT Phase 2 clinical trial of RE104 for the treatment of postpartum depression (PPD). RE104 was designed to be a safe, fast-acting, single-dose therapy to benefit patients suffering from underserved mental health disorders, including PPD. The RECONNECT Phase 2 clinical trial (NCT06342310) is a multicenter, randomized, double-blind, parallel-group, active dose-controlled clinical trial evaluating the safety and efficacy of a single subcutaneous dose of RE104 in adult female patients with moderate-to-severe PPD. The primary endpoint of the trial is the change in total Montgomery-Åsberg Depression Rating Scale (MADRS) score, a 10-item clinician rated scale measuring depression severity from baseline, at Day 7. Key secondary endpoints include the change in total MADRS score from baseline at Day 1, 14 and 28, MADRS response indicating a = 50% reduction in symptoms, MADRS remission with a score of = 10, as well as safety and tolerability. The Company’s lead product candidate, RE104, is a proprietary, potential best-in-class, patented prodrug of 4-OH-DiPT. Reunion designed RE104 to deliver a short duration psychedelic experience compared to longer duration psychedelics like psilocybin. In a Phase 1 clinical trial, RE104 produced a psychedelic state similar in intensity and quality to psilocybin, but lasting only about half the time (3-4 hours), while demonstrating a similar, favorable safety profile. RE104 is currently being evaluated in the RECONNECT Phase 2 (NCT06342310) clinical trial, a multicenter, randomized, double-blind, active dose-controlled clinical trial in moderate-to-severe Postpartum Depression (PPD) patients. Reunion is actively evaluating the use of RE104 in additional neuropsychiatric indications, including adjustment disorder in cancer patients, where there remains a significant unmet need that is not addressed by the current standard of care. Postpartum depression (PPD) is one of the most common medical complications during and after pregnancy and is estimated to affect approximately 10-15% of all mothers of newborns. PPD is a form of major depression that can severely impact women and their families. According to the Centers for Disease Control and Prevention, the leading underlying cause of pregnancy-related death during the first postpartum year are due to mental health conditions, with suicide being the leading manner of death. Women suffering from PPD often experience significant changes in mood, appetite and sleep contributing to feelings of hopelessness, lack of concentration, loss of energy, poor self-esteem and maternal disinterest.お知らせ • May 03+ 1 more updateReunion Neuroscience Inc. announced that it has received CAD 103 million in funding from a group of investorsOn May 2, 2024, Reunion Neuroscience Inc. closed the transaction. The company has received $94,500,000 in its second and final tranche, bringing the total funds raised to $103,000,000 in the transaction. The transaction was co-led by new investors, MPM Asset Management, L.L.C. and Novo Holdings A/S and also included participation from new investors, Arkin Bio-Capital, a fund managed by Arkin Holdings, Mitsui & Co. Global Investment, Inc., Plaisance Capital LLC, FemHealth Ventures LLC, Palo Santo as well as a syndicate composed of top-tier institutional healthcare investors.お知らせ • Sep 20Reunion Neuroscience Inc. Announces FDA Clearance of IND Application to Initiate A Phase 2 Study of Re104 for the Treatment of Postpartum DepressionReunion Neuroscience Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to initiate a Phase 2 study of RE104, a novel serotonergic psychedelic compound, for the treatment of postpartum depression (PPD). The Phase 2 study, the RECONNECT Trial, is a multicenter, randomized, double-blind, parallel-group, active-dose placebo-controlled study, which will evaluate the safety and efficacy of a single subcutaneous dose of RE104 in adult female patients with PPD. The study is expected to begin in fourth quarter 2023 with a targeted data readout in late 2024.お知らせ • Aug 19Reunion Neuroscience Inc. Files Form 15Reunion Neuroscience Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Shares under the Securities Exchange Act of 1934, as amended.お知らせ • Aug 03+ 1 more updateMPM Asset Management, L.L.C. acquired Reunion Neuroscience Inc. (TSX:REUN) in a going private transaction.MPM Asset Management, L.L.C. entered into a definitive arrangement agreement to acquire Reunion Neuroscience Inc. (TSX:REUN) for CAD 17.8 million in a going private transaction on May 31, 2023. MPM would acquire Reunion in an all-cash transaction valued at approximately $13.1 million (CAD 17,809,536). Pursuant to the terms and conditions, Reunion shareholders shall receive CAD 1.52 per share. Post deal completion, Reunion will no longer be traded or listed on any public securities exchange and will be wholly-owned by affiliates of MPM. Reunion's board of directors has unanimously approved the transaction. In case of termination of the transaction under certain circumstances, Reunion Neuroscience will be required to pay a termination fee of $0.8 million (CAD 1,067,000). Completion of the Arrangement remains subject to the approval of the Shareholders at the Meeting, obtaining all applicable regulatory approvals, including approval of the Ontario Superior Court of Justice (Commercial List) (the "Court") of the Arrangement and the net cash held by the Company being equal to or greater than $8 million (CAD 10,876,052) as of the close of business. Shareholders meeting is scheduled on July 12, 2023. On July 12, 2023 at the Meeting, shareholders voted in favor of a special resolution to approve the proposed plan of arrangement under Section 192 of the Canada Business Corporations Act. As of July 14, 2023, the transaction has received the final Ontario Superior Court of Justice approval. The deal is expected to close in the calendar third quarter of 2023. As of July 14, 2023, the transaction is expected to close on or about July 21, 2023.Oppenheimer & Co. Inc. is serving as exclusive financial advisor to the Special Committee of the Board of Directors of Reunion and PI Financial Corp. rendered a fairness opinion to Reunion, and Aaron Sonshine and Kris Hanc of Bennett Jones LLP and Steven M. Cohen, Veronica DiCamillo and Jacqueline Berman of Morgan, Lewis & Bockius LLP are serving as legal advisors. Jonathan See and Rami Chalabi of McCarthy Tétrault LLP and Wilmer Cutler Pickering Hale and Dorr LLP are serving as legal advisors to MPM. Computershare Investor Services Inc. is the depository bank for Reunion.MPM Asset Management, L.L.C. acquired Reunion Neuroscience Inc. (TSX:REUN) in a going private transaction on August 1, 2023. With the completion of the Arrangement, the Shares are expected to be de-listed from the Toronto Stock Exchange on the close of markets on or around August 2, 2023. The Company is in the process of applying to cease to be a reporting issuer under applicable Canadian securities laws. The Shares will be delisted from the Nasdaq Global Select Market and deregistered under the Securities Exchange Act of 1934, as amended.お知らせ • Aug 02Reunion Neuroscience's Shares to Be De-Listed from the Toronto Stock Exchange on the Close of Markets on or Around August 2, 2023Reunion Neuroscience Inc. and MPM BioImpact ("MPM") announced the completion of the previously announced plan of arrangement (the "Arrangement") effective August 1, 2023, whereby MPM acquired Reunion in an all-cash transaction valued at approximately USD 13.1 million by way of a court-approved plan of arrangement under Section 192 of the Canada Business Corporations Act. Pursuant to the terms and conditions of a definitive arrangement agreement entered into by Reunion and affiliates of MPM on May 31, 2023, all holders of outstanding common shares ("Shares") of Reunion are entitled to receive USD 1.12 in cash for each Share held immediately prior to the effective time of the Arrangement. As previously announced, the Arrangement was approved by shareholders of the Company at its special meeting of shareholders held on July 12, 2023 and by the Ontario Superior Court of Justice (Commercial List) on July 14, 2023. With the completion of the Arrangement, the Shares are expected to be de-listed from the Toronto Stock Exchange on the close of markets on or around August 2, 2023. The Company is in the process of applying to cease to be a reporting issuer under applicable Canadian securities laws. The Shares will be delisted from the Nasdaq Global Select Market and deregistered under the Securities Exchange Act of 1934, as amended.New Risk • Jun 29New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$28m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$28m free cash flow). Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings are forecast to decline by an average of 14% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (CA$83m net loss in 3 years). Market cap is less than US$100m (US$12.8m market cap).お知らせ • Jun 03MPM Asset Management, L.L.C. entered into a definitive arrangement agreement to acquire Reunion Neuroscience Inc. (TSX:REUN) for CAD 17.7 million in a going private transaction.MPM Asset Management, L.L.C. entered into a definitive arrangement agreement to acquire Reunion Neuroscience Inc. (TSX:REUN) for CAD 17.7 million in a going private transaction on May 31, 2023. MPM would acquire Reunion in an all-cash transaction valued at approximately $13.1 million (CAD 17,809,536). Pursuant to the terms and conditions, Reunion shareholders shall receive CAD 1.52 per share. Post deal completion, Reunion will no longer be traded or listed on any public securities exchange and will be wholly-owned by affiliates of MPM. Reunion's board of directors has unanimously approved the transaction. Completion of the Arrangement remains subject to the approval of the Shareholders at the Meeting, obtaining all applicable regulatory approvals, including approval of the Ontario Superior Court of Justice (Commercial List) (the "Court") of the Arrangement and the net cash held by the Company being equal to or greater than $8 million (CAD 10,876,052) as of the close of business. Shareholders meeting is scheduled on July 12, 2023. The deal is expected to close in the calendar third quarter of 2023. Oppenheimer & Co. Inc. is serving as exclusive financial advisor to the Special Committee of the Board of Directors of Reunion and PI Financial Corp. rendered a fairness opinion to Reunion, and Bennett Jones LLP and Steven Cohen, Veronica DiCamillo and Jacqueline Berman of Morgan, Lewis & Bockius LLP are serving as legal advisors. McCarthy Tétrault LLP and Wilmer Cutler Pickering Hale and Dorr LLP are serving as legal advisors to MPM.お知らせ • Feb 03Reunion Neuroscience Inc. to Report Q3, 2023 Results on Feb 14, 2023Reunion Neuroscience Inc. announced that they will report Q3, 2023 results Pre-Market on Feb 14, 2023お知らせ • Jan 19Reunion Neuroscience Appoints Robert Alexander as Chief Medical OfficerReunion Neuroscience Inc. announced that it has appointed Robert Alexander, M.D. as the Company’s Chief Medical Officer, effective immediately. Dr. Alexander will report to Greg Mayes, Reunion’s President and CEO. Dr. Alexander previously served as Vice President and Head, Clinical Science, in the Neuroscience Therapeutic Area Unit at Takeda Pharmaceuticals, managing all clinical trials in neuroscience from Phase 1 through 3. Prior to Takeda, Dr. Alexander served as Chief Medical Officer, BioTherapeutics, at Pfizer, directing clinical pharmacology and statistics groups while simultaneously holding the position of Vice President and Head of the Clinical Neuroscience and Pain Research Unit at the company. Dr. Alexander also held various other senior leadership roles at AstraZeneca, GlaxoSmithKline (GSK) and Merck & Co and received his M.D. degree from The University of Chicago Pritzker School of Medicine. He is certified by the American Board of Psychiatry and Neurology and specializes in psychopharmacology, having conducted or supervised clinical studies in a broad range of neurologic and psychiatric indications.お知らせ • Jan 10Reunion Neuroscience Inc. Completes Interim Data Analysis for Phase 1 Clinical Trial with Novel Serotonergic Psychedelic Re104Reunion Neuroscience Inc. announced that the Company has completed the interim data analysis for its Phase 1 clinical trial with lead asset RE104, a unique 4-OH-DiPT prodrug. RE104 is a proprietary, novel serotonergic sychedelic compound that Reunion is developing as a potential fast-acting and durable treatment for patients suffering from postpartum depression and other mental health conditions. In this first-in-human, Phase 1 study, RE104 was shown to be safe and well tolerated, with no serious or severe adverse events. The interim analysis included 32 healthy volunteers across four ascending dose cohorts, with two of the eight subjects in each cohort receiving placebo. RE104 showed robust and pervasive pharmacodynamic effects with a shorter duration of psychedelic experience relative to published data with psilocybin (approximately three to four hours for RE104 versus six to eight hours for psilocybin). Reunion also identified a dose level whereby the majority of participants receiving a single administration of RE104 achieved a "complete mystical experience," defined as a score of at least 60% in each of the four domains of the validated Mystical Experience Questionnaire (MEQ30). A complete mystical experience has been shown to correlate with psychedelic treatment responses in clinical trials of patients with depression, anxiety and substance use disorder.(3-5)Reunion plans to share results from its Phase 1 study with the U.S. Food and Drug Administration (FDA) as part of a pre-Investigational New Drug (IND) meeting in preparation for Phase 2 development in postpartum depression. The Company will also submit the data to an upcoming 2023 major medical congress. While completing the preplanned interim analysis, and per the recommendation of the Safety Review Committee (SRC), Reunion has continued with dose escalation and initiated a fifth cohort. The Phase 1 protocol also includes the option to dose a sixth cohort with eight subjects should the SRC or the Company seek additional safety, pharmacokinetics and pharmacodynamics data.Board Change • Nov 16High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. President, CEO & Director Greg Mayes was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Board Change • Nov 03High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 7 experienced directors. No highly experienced directors. Co-Founder & Non-Independent Director Hannan Fleiman is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Seeking Alpha • Oct 07Reunion Neuroscience announces resignation of director, general counselReunion Neuroscience (NASDAQ:REUN) on Friday announced the resignations of director Ronan Levy and general counsel & corporate secretary Paula Amy Hewitt. The company appointed CEO Greg Mayes to replace Levy as director. CFO Donna Wong as appointed as corporate secretary in place of Hewitt. REUN stock +4.9% to $1.94 after hours.Seeking Alpha • Sep 28Reunion Neuroscience appoints Greg Mayes as President and CEOReunion Neuroscience (NASDAQ:REUN) appoints Greg Mayes as President and Chief Executive Officer. Most recently he served as the President and CEO of Antios Therapeutics. It is anticipated that Mr. Mayes will be appointed to the Reunion Board of Directors to replace Ronan Levy, Reunion co-founder and current Chairman and CEO of Field Trip Health & Wellness Ltd., who will step down from Reunion’s Board in October 2022.Board Change • Aug 25High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 7 experienced directors. No highly experienced directors. Independent Director Dieter Weinand is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Seeking Alpha • Aug 15Field Trip Health GAAP EPS of -C$0.09Field Trip Health press release (NASDAQ:FTRP): Q1 GAAP EPS of -C$0.09. As of June 30, 2022, the Company had unrestricted cash, cash equivalents and short-term investments of C$52.3 million, including C$4.1 million held at the Clinic Operations. Shares +4.42% AH.Seeking Alpha • Jun 29Field Trip Health receives final court approval for clinics business spin-outPsychedelic therapies company Field Trip Health (NASDAQ:FTRP) said it has received final court approval for the spin-out of its clinics business to Field Trip Health & Wellness. The spin-out is to be executed by way of a plan of arrangement, with the closing subject to regulatory approvals. As part of the arrangement, each share of FTRP will be exchanged for one common share of FTRP, to be renamed Reunion Neuroscience on consummation of the arrangement, and ~0.86 common share of Field Trip Health & Wellness. The closing of the arrangement is set to occur on or around August. Field Trip Health & Wellness will list on the TSX Venture Exchange, subject to the exchange's approval. Additionally, Field Trip Health closed a private placement of subscription receipts of Field Trip Health & Wellness. The private placement, led by Bloom Burton Securities, involved an issue price of C$0.50 per receipt, with aggregate gross proceeds of C$2.1M. The net proceeds of the offering will be used for clinic operating expenses, working capital, arrangement expenses as well as for general corporate purposes. Source: Press ReleaseBoard Change • Apr 27High number of new directorsIndependent Lead Director Barry Fishman was the last director to join the board, commencing their role in 2021.Board Change • Mar 31High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 6 experienced directors. No highly experienced directors. CO-Founder, President & Director Hannan Fleiman is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Reported Earnings • Feb 17Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2022 results: CA$0.26 loss per share (down from CA$0.22 loss in 3Q 2021). Net loss: CA$15.0m (loss widened 81% from 3Q 2021). Revenue missed analyst estimates by 11%. Earnings per share (EPS) exceeded analyst estimates by 14%. Over the next year, revenue is forecast to grow 440%, compared to a 10.0% growth forecast for the industry in the US.Reported Earnings • Nov 18Second quarter 2022 earnings released: CA$0.23 loss per share (vs CA$0.16 loss in 2Q 2021)Second quarter 2022 results: Net loss: CA$13.0m (loss widened 231% from 2Q 2021).Board Change • Sep 14Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Member of Medical Advisory Board Matt Johnson was the last director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Sep 08Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Member of Medical Advisory Board Matt Johnson was the last director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 18First quarter 2022 earnings released: CA$0.22 loss per share (vs CA$1.69 loss in 1Q 2021)First quarter 2022 results: Net loss: CA$12.5m (loss widened 324% from 1Q 2021).Board Change • Jul 30Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Member of Medical Advisory Board Matt Johnson was the last director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.株主還元REUNUS BiotechsUS 市場7D0.9%-1.4%-1.4%1Y-73.0%28.1%16.4%株主還元を見る業界別リターン: REUN過去 1 年間で28.1 % の収益を上げたUS Biotechs業界を下回りました。リターン対市場: REUNは、過去 1 年間で16.4 % のリターンを上げたUS市場を下回りました。価格変動Is REUN's price volatile compared to industry and market?REUN volatilityREUN Average Weekly Movement17.1%Biotechs Industry Average Movement10.2%Market Average Movement7.1%10% most volatile stocks in US Market16.3%10% least volatile stocks in US Market3.2%安定した株価: REUNの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: REUNの weekly volatility ( 17% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト200816Greg Mayesreunionneuro.comもっと見るReunion Neuroscience Inc. 基礎のまとめReunion Neuroscience の収益と売上を時価総額と比較するとどうか。REUN 基礎統計学時価総額US$12.47m収益（TTM）-US$28.55m売上高(TTM)n/a0.0xP/Sレシオ-0.4xPER（株価収益率REUN は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計REUN 損益計算書（TTM）収益CA$0売上原価CA$0売上総利益CA$0その他の費用CA$38.10m収益-CA$38.10m直近の収益報告Mar 31, 2023次回決算日該当なし一株当たり利益（EPS）-3.25グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率0%REUN の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/08/03 12:59終値2023/07/31 00:00収益2023/03/31年間収益2023/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Reunion Neuroscience Inc. これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7 アナリスト機関David MartinBloom Burton & Co.Elemer PirosD. Boral Capital LLC.Patrick TrucchioH.C. Wainwright & Co.4 その他のアナリストを表示
お知らせ • Jul 23Reunion Neuroscience Inc. Announces First Patient Dosed in Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum DepressionReunion Neuroscience Inc. announced that the first patient has been dosed in the RECONNECT Phase 2 clinical trial of RE104 for the treatment of postpartum depression (PPD). RE104 was designed to be a safe, fast-acting, single-dose therapy to benefit patients suffering from underserved mental health disorders, including PPD. The RECONNECT Phase 2 clinical trial (NCT06342310) is a multicenter, randomized, double-blind, parallel-group, active dose-controlled clinical trial evaluating the safety and efficacy of a single subcutaneous dose of RE104 in adult female patients with moderate-to-severe PPD. The primary endpoint of the trial is the change in total Montgomery-Åsberg Depression Rating Scale (MADRS) score, a 10-item clinician rated scale measuring depression severity from baseline, at Day 7. Key secondary endpoints include the change in total MADRS score from baseline at Day 1, 14 and 28, MADRS response indicating a = 50% reduction in symptoms, MADRS remission with a score of = 10, as well as safety and tolerability. The Company’s lead product candidate, RE104, is a proprietary, potential best-in-class, patented prodrug of 4-OH-DiPT. Reunion designed RE104 to deliver a short duration psychedelic experience compared to longer duration psychedelics like psilocybin. In a Phase 1 clinical trial, RE104 produced a psychedelic state similar in intensity and quality to psilocybin, but lasting only about half the time (3-4 hours), while demonstrating a similar, favorable safety profile. RE104 is currently being evaluated in the RECONNECT Phase 2 (NCT06342310) clinical trial, a multicenter, randomized, double-blind, active dose-controlled clinical trial in moderate-to-severe Postpartum Depression (PPD) patients. Reunion is actively evaluating the use of RE104 in additional neuropsychiatric indications, including adjustment disorder in cancer patients, where there remains a significant unmet need that is not addressed by the current standard of care. Postpartum depression (PPD) is one of the most common medical complications during and after pregnancy and is estimated to affect approximately 10-15% of all mothers of newborns. PPD is a form of major depression that can severely impact women and their families. According to the Centers for Disease Control and Prevention, the leading underlying cause of pregnancy-related death during the first postpartum year are due to mental health conditions, with suicide being the leading manner of death. Women suffering from PPD often experience significant changes in mood, appetite and sleep contributing to feelings of hopelessness, lack of concentration, loss of energy, poor self-esteem and maternal disinterest.
お知らせ • May 03+ 1 more updateReunion Neuroscience Inc. announced that it has received CAD 103 million in funding from a group of investorsOn May 2, 2024, Reunion Neuroscience Inc. closed the transaction. The company has received $94,500,000 in its second and final tranche, bringing the total funds raised to $103,000,000 in the transaction. The transaction was co-led by new investors, MPM Asset Management, L.L.C. and Novo Holdings A/S and also included participation from new investors, Arkin Bio-Capital, a fund managed by Arkin Holdings, Mitsui & Co. Global Investment, Inc., Plaisance Capital LLC, FemHealth Ventures LLC, Palo Santo as well as a syndicate composed of top-tier institutional healthcare investors.
お知らせ • Sep 20Reunion Neuroscience Inc. Announces FDA Clearance of IND Application to Initiate A Phase 2 Study of Re104 for the Treatment of Postpartum DepressionReunion Neuroscience Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to initiate a Phase 2 study of RE104, a novel serotonergic psychedelic compound, for the treatment of postpartum depression (PPD). The Phase 2 study, the RECONNECT Trial, is a multicenter, randomized, double-blind, parallel-group, active-dose placebo-controlled study, which will evaluate the safety and efficacy of a single subcutaneous dose of RE104 in adult female patients with PPD. The study is expected to begin in fourth quarter 2023 with a targeted data readout in late 2024.
お知らせ • Aug 19Reunion Neuroscience Inc. Files Form 15Reunion Neuroscience Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Shares under the Securities Exchange Act of 1934, as amended.
お知らせ • Aug 03+ 1 more updateMPM Asset Management, L.L.C. acquired Reunion Neuroscience Inc. (TSX:REUN) in a going private transaction.MPM Asset Management, L.L.C. entered into a definitive arrangement agreement to acquire Reunion Neuroscience Inc. (TSX:REUN) for CAD 17.8 million in a going private transaction on May 31, 2023. MPM would acquire Reunion in an all-cash transaction valued at approximately $13.1 million (CAD 17,809,536). Pursuant to the terms and conditions, Reunion shareholders shall receive CAD 1.52 per share. Post deal completion, Reunion will no longer be traded or listed on any public securities exchange and will be wholly-owned by affiliates of MPM. Reunion's board of directors has unanimously approved the transaction. In case of termination of the transaction under certain circumstances, Reunion Neuroscience will be required to pay a termination fee of $0.8 million (CAD 1,067,000). Completion of the Arrangement remains subject to the approval of the Shareholders at the Meeting, obtaining all applicable regulatory approvals, including approval of the Ontario Superior Court of Justice (Commercial List) (the "Court") of the Arrangement and the net cash held by the Company being equal to or greater than $8 million (CAD 10,876,052) as of the close of business. Shareholders meeting is scheduled on July 12, 2023. On July 12, 2023 at the Meeting, shareholders voted in favor of a special resolution to approve the proposed plan of arrangement under Section 192 of the Canada Business Corporations Act. As of July 14, 2023, the transaction has received the final Ontario Superior Court of Justice approval. The deal is expected to close in the calendar third quarter of 2023. As of July 14, 2023, the transaction is expected to close on or about July 21, 2023.Oppenheimer & Co. Inc. is serving as exclusive financial advisor to the Special Committee of the Board of Directors of Reunion and PI Financial Corp. rendered a fairness opinion to Reunion, and Aaron Sonshine and Kris Hanc of Bennett Jones LLP and Steven M. Cohen, Veronica DiCamillo and Jacqueline Berman of Morgan, Lewis & Bockius LLP are serving as legal advisors. Jonathan See and Rami Chalabi of McCarthy Tétrault LLP and Wilmer Cutler Pickering Hale and Dorr LLP are serving as legal advisors to MPM. Computershare Investor Services Inc. is the depository bank for Reunion.MPM Asset Management, L.L.C. acquired Reunion Neuroscience Inc. (TSX:REUN) in a going private transaction on August 1, 2023. With the completion of the Arrangement, the Shares are expected to be de-listed from the Toronto Stock Exchange on the close of markets on or around August 2, 2023. The Company is in the process of applying to cease to be a reporting issuer under applicable Canadian securities laws. The Shares will be delisted from the Nasdaq Global Select Market and deregistered under the Securities Exchange Act of 1934, as amended.
お知らせ • Aug 02Reunion Neuroscience's Shares to Be De-Listed from the Toronto Stock Exchange on the Close of Markets on or Around August 2, 2023Reunion Neuroscience Inc. and MPM BioImpact ("MPM") announced the completion of the previously announced plan of arrangement (the "Arrangement") effective August 1, 2023, whereby MPM acquired Reunion in an all-cash transaction valued at approximately USD 13.1 million by way of a court-approved plan of arrangement under Section 192 of the Canada Business Corporations Act. Pursuant to the terms and conditions of a definitive arrangement agreement entered into by Reunion and affiliates of MPM on May 31, 2023, all holders of outstanding common shares ("Shares") of Reunion are entitled to receive USD 1.12 in cash for each Share held immediately prior to the effective time of the Arrangement. As previously announced, the Arrangement was approved by shareholders of the Company at its special meeting of shareholders held on July 12, 2023 and by the Ontario Superior Court of Justice (Commercial List) on July 14, 2023. With the completion of the Arrangement, the Shares are expected to be de-listed from the Toronto Stock Exchange on the close of markets on or around August 2, 2023. The Company is in the process of applying to cease to be a reporting issuer under applicable Canadian securities laws. The Shares will be delisted from the Nasdaq Global Select Market and deregistered under the Securities Exchange Act of 1934, as amended.
お知らせ • Jul 23Reunion Neuroscience Inc. Announces First Patient Dosed in Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum DepressionReunion Neuroscience Inc. announced that the first patient has been dosed in the RECONNECT Phase 2 clinical trial of RE104 for the treatment of postpartum depression (PPD). RE104 was designed to be a safe, fast-acting, single-dose therapy to benefit patients suffering from underserved mental health disorders, including PPD. The RECONNECT Phase 2 clinical trial (NCT06342310) is a multicenter, randomized, double-blind, parallel-group, active dose-controlled clinical trial evaluating the safety and efficacy of a single subcutaneous dose of RE104 in adult female patients with moderate-to-severe PPD. The primary endpoint of the trial is the change in total Montgomery-Åsberg Depression Rating Scale (MADRS) score, a 10-item clinician rated scale measuring depression severity from baseline, at Day 7. Key secondary endpoints include the change in total MADRS score from baseline at Day 1, 14 and 28, MADRS response indicating a = 50% reduction in symptoms, MADRS remission with a score of = 10, as well as safety and tolerability. The Company’s lead product candidate, RE104, is a proprietary, potential best-in-class, patented prodrug of 4-OH-DiPT. Reunion designed RE104 to deliver a short duration psychedelic experience compared to longer duration psychedelics like psilocybin. In a Phase 1 clinical trial, RE104 produced a psychedelic state similar in intensity and quality to psilocybin, but lasting only about half the time (3-4 hours), while demonstrating a similar, favorable safety profile. RE104 is currently being evaluated in the RECONNECT Phase 2 (NCT06342310) clinical trial, a multicenter, randomized, double-blind, active dose-controlled clinical trial in moderate-to-severe Postpartum Depression (PPD) patients. Reunion is actively evaluating the use of RE104 in additional neuropsychiatric indications, including adjustment disorder in cancer patients, where there remains a significant unmet need that is not addressed by the current standard of care. Postpartum depression (PPD) is one of the most common medical complications during and after pregnancy and is estimated to affect approximately 10-15% of all mothers of newborns. PPD is a form of major depression that can severely impact women and their families. According to the Centers for Disease Control and Prevention, the leading underlying cause of pregnancy-related death during the first postpartum year are due to mental health conditions, with suicide being the leading manner of death. Women suffering from PPD often experience significant changes in mood, appetite and sleep contributing to feelings of hopelessness, lack of concentration, loss of energy, poor self-esteem and maternal disinterest.
お知らせ • May 03+ 1 more updateReunion Neuroscience Inc. announced that it has received CAD 103 million in funding from a group of investorsOn May 2, 2024, Reunion Neuroscience Inc. closed the transaction. The company has received $94,500,000 in its second and final tranche, bringing the total funds raised to $103,000,000 in the transaction. The transaction was co-led by new investors, MPM Asset Management, L.L.C. and Novo Holdings A/S and also included participation from new investors, Arkin Bio-Capital, a fund managed by Arkin Holdings, Mitsui & Co. Global Investment, Inc., Plaisance Capital LLC, FemHealth Ventures LLC, Palo Santo as well as a syndicate composed of top-tier institutional healthcare investors.
お知らせ • Sep 20Reunion Neuroscience Inc. Announces FDA Clearance of IND Application to Initiate A Phase 2 Study of Re104 for the Treatment of Postpartum DepressionReunion Neuroscience Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to initiate a Phase 2 study of RE104, a novel serotonergic psychedelic compound, for the treatment of postpartum depression (PPD). The Phase 2 study, the RECONNECT Trial, is a multicenter, randomized, double-blind, parallel-group, active-dose placebo-controlled study, which will evaluate the safety and efficacy of a single subcutaneous dose of RE104 in adult female patients with PPD. The study is expected to begin in fourth quarter 2023 with a targeted data readout in late 2024.
お知らせ • Aug 19Reunion Neuroscience Inc. Files Form 15Reunion Neuroscience Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Shares under the Securities Exchange Act of 1934, as amended.
お知らせ • Aug 03+ 1 more updateMPM Asset Management, L.L.C. acquired Reunion Neuroscience Inc. (TSX:REUN) in a going private transaction.MPM Asset Management, L.L.C. entered into a definitive arrangement agreement to acquire Reunion Neuroscience Inc. (TSX:REUN) for CAD 17.8 million in a going private transaction on May 31, 2023. MPM would acquire Reunion in an all-cash transaction valued at approximately $13.1 million (CAD 17,809,536). Pursuant to the terms and conditions, Reunion shareholders shall receive CAD 1.52 per share. Post deal completion, Reunion will no longer be traded or listed on any public securities exchange and will be wholly-owned by affiliates of MPM. Reunion's board of directors has unanimously approved the transaction. In case of termination of the transaction under certain circumstances, Reunion Neuroscience will be required to pay a termination fee of $0.8 million (CAD 1,067,000). Completion of the Arrangement remains subject to the approval of the Shareholders at the Meeting, obtaining all applicable regulatory approvals, including approval of the Ontario Superior Court of Justice (Commercial List) (the "Court") of the Arrangement and the net cash held by the Company being equal to or greater than $8 million (CAD 10,876,052) as of the close of business. Shareholders meeting is scheduled on July 12, 2023. On July 12, 2023 at the Meeting, shareholders voted in favor of a special resolution to approve the proposed plan of arrangement under Section 192 of the Canada Business Corporations Act. As of July 14, 2023, the transaction has received the final Ontario Superior Court of Justice approval. The deal is expected to close in the calendar third quarter of 2023. As of July 14, 2023, the transaction is expected to close on or about July 21, 2023.Oppenheimer & Co. Inc. is serving as exclusive financial advisor to the Special Committee of the Board of Directors of Reunion and PI Financial Corp. rendered a fairness opinion to Reunion, and Aaron Sonshine and Kris Hanc of Bennett Jones LLP and Steven M. Cohen, Veronica DiCamillo and Jacqueline Berman of Morgan, Lewis & Bockius LLP are serving as legal advisors. Jonathan See and Rami Chalabi of McCarthy Tétrault LLP and Wilmer Cutler Pickering Hale and Dorr LLP are serving as legal advisors to MPM. Computershare Investor Services Inc. is the depository bank for Reunion.MPM Asset Management, L.L.C. acquired Reunion Neuroscience Inc. (TSX:REUN) in a going private transaction on August 1, 2023. With the completion of the Arrangement, the Shares are expected to be de-listed from the Toronto Stock Exchange on the close of markets on or around August 2, 2023. The Company is in the process of applying to cease to be a reporting issuer under applicable Canadian securities laws. The Shares will be delisted from the Nasdaq Global Select Market and deregistered under the Securities Exchange Act of 1934, as amended.
お知らせ • Aug 02Reunion Neuroscience's Shares to Be De-Listed from the Toronto Stock Exchange on the Close of Markets on or Around August 2, 2023Reunion Neuroscience Inc. and MPM BioImpact ("MPM") announced the completion of the previously announced plan of arrangement (the "Arrangement") effective August 1, 2023, whereby MPM acquired Reunion in an all-cash transaction valued at approximately USD 13.1 million by way of a court-approved plan of arrangement under Section 192 of the Canada Business Corporations Act. Pursuant to the terms and conditions of a definitive arrangement agreement entered into by Reunion and affiliates of MPM on May 31, 2023, all holders of outstanding common shares ("Shares") of Reunion are entitled to receive USD 1.12 in cash for each Share held immediately prior to the effective time of the Arrangement. As previously announced, the Arrangement was approved by shareholders of the Company at its special meeting of shareholders held on July 12, 2023 and by the Ontario Superior Court of Justice (Commercial List) on July 14, 2023. With the completion of the Arrangement, the Shares are expected to be de-listed from the Toronto Stock Exchange on the close of markets on or around August 2, 2023. The Company is in the process of applying to cease to be a reporting issuer under applicable Canadian securities laws. The Shares will be delisted from the Nasdaq Global Select Market and deregistered under the Securities Exchange Act of 1934, as amended.
New Risk • Jun 29New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$28m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$28m free cash flow). Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings are forecast to decline by an average of 14% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (CA$83m net loss in 3 years). Market cap is less than US$100m (US$12.8m market cap).
お知らせ • Jun 03MPM Asset Management, L.L.C. entered into a definitive arrangement agreement to acquire Reunion Neuroscience Inc. (TSX:REUN) for CAD 17.7 million in a going private transaction.MPM Asset Management, L.L.C. entered into a definitive arrangement agreement to acquire Reunion Neuroscience Inc. (TSX:REUN) for CAD 17.7 million in a going private transaction on May 31, 2023. MPM would acquire Reunion in an all-cash transaction valued at approximately $13.1 million (CAD 17,809,536). Pursuant to the terms and conditions, Reunion shareholders shall receive CAD 1.52 per share. Post deal completion, Reunion will no longer be traded or listed on any public securities exchange and will be wholly-owned by affiliates of MPM. Reunion's board of directors has unanimously approved the transaction. Completion of the Arrangement remains subject to the approval of the Shareholders at the Meeting, obtaining all applicable regulatory approvals, including approval of the Ontario Superior Court of Justice (Commercial List) (the "Court") of the Arrangement and the net cash held by the Company being equal to or greater than $8 million (CAD 10,876,052) as of the close of business. Shareholders meeting is scheduled on July 12, 2023. The deal is expected to close in the calendar third quarter of 2023. Oppenheimer & Co. Inc. is serving as exclusive financial advisor to the Special Committee of the Board of Directors of Reunion and PI Financial Corp. rendered a fairness opinion to Reunion, and Bennett Jones LLP and Steven Cohen, Veronica DiCamillo and Jacqueline Berman of Morgan, Lewis & Bockius LLP are serving as legal advisors. McCarthy Tétrault LLP and Wilmer Cutler Pickering Hale and Dorr LLP are serving as legal advisors to MPM.
お知らせ • Feb 03Reunion Neuroscience Inc. to Report Q3, 2023 Results on Feb 14, 2023Reunion Neuroscience Inc. announced that they will report Q3, 2023 results Pre-Market on Feb 14, 2023
お知らせ • Jan 19Reunion Neuroscience Appoints Robert Alexander as Chief Medical OfficerReunion Neuroscience Inc. announced that it has appointed Robert Alexander, M.D. as the Company’s Chief Medical Officer, effective immediately. Dr. Alexander will report to Greg Mayes, Reunion’s President and CEO. Dr. Alexander previously served as Vice President and Head, Clinical Science, in the Neuroscience Therapeutic Area Unit at Takeda Pharmaceuticals, managing all clinical trials in neuroscience from Phase 1 through 3. Prior to Takeda, Dr. Alexander served as Chief Medical Officer, BioTherapeutics, at Pfizer, directing clinical pharmacology and statistics groups while simultaneously holding the position of Vice President and Head of the Clinical Neuroscience and Pain Research Unit at the company. Dr. Alexander also held various other senior leadership roles at AstraZeneca, GlaxoSmithKline (GSK) and Merck & Co and received his M.D. degree from The University of Chicago Pritzker School of Medicine. He is certified by the American Board of Psychiatry and Neurology and specializes in psychopharmacology, having conducted or supervised clinical studies in a broad range of neurologic and psychiatric indications.
お知らせ • Jan 10Reunion Neuroscience Inc. Completes Interim Data Analysis for Phase 1 Clinical Trial with Novel Serotonergic Psychedelic Re104Reunion Neuroscience Inc. announced that the Company has completed the interim data analysis for its Phase 1 clinical trial with lead asset RE104, a unique 4-OH-DiPT prodrug. RE104 is a proprietary, novel serotonergic sychedelic compound that Reunion is developing as a potential fast-acting and durable treatment for patients suffering from postpartum depression and other mental health conditions. In this first-in-human, Phase 1 study, RE104 was shown to be safe and well tolerated, with no serious or severe adverse events. The interim analysis included 32 healthy volunteers across four ascending dose cohorts, with two of the eight subjects in each cohort receiving placebo. RE104 showed robust and pervasive pharmacodynamic effects with a shorter duration of psychedelic experience relative to published data with psilocybin (approximately three to four hours for RE104 versus six to eight hours for psilocybin). Reunion also identified a dose level whereby the majority of participants receiving a single administration of RE104 achieved a "complete mystical experience," defined as a score of at least 60% in each of the four domains of the validated Mystical Experience Questionnaire (MEQ30). A complete mystical experience has been shown to correlate with psychedelic treatment responses in clinical trials of patients with depression, anxiety and substance use disorder.(3-5)Reunion plans to share results from its Phase 1 study with the U.S. Food and Drug Administration (FDA) as part of a pre-Investigational New Drug (IND) meeting in preparation for Phase 2 development in postpartum depression. The Company will also submit the data to an upcoming 2023 major medical congress. While completing the preplanned interim analysis, and per the recommendation of the Safety Review Committee (SRC), Reunion has continued with dose escalation and initiated a fifth cohort. The Phase 1 protocol also includes the option to dose a sixth cohort with eight subjects should the SRC or the Company seek additional safety, pharmacokinetics and pharmacodynamics data.
Board Change • Nov 16High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. President, CEO & Director Greg Mayes was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Board Change • Nov 03High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 7 experienced directors. No highly experienced directors. Co-Founder & Non-Independent Director Hannan Fleiman is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Seeking Alpha • Oct 07Reunion Neuroscience announces resignation of director, general counselReunion Neuroscience (NASDAQ:REUN) on Friday announced the resignations of director Ronan Levy and general counsel & corporate secretary Paula Amy Hewitt. The company appointed CEO Greg Mayes to replace Levy as director. CFO Donna Wong as appointed as corporate secretary in place of Hewitt. REUN stock +4.9% to $1.94 after hours.
Seeking Alpha • Sep 28Reunion Neuroscience appoints Greg Mayes as President and CEOReunion Neuroscience (NASDAQ:REUN) appoints Greg Mayes as President and Chief Executive Officer. Most recently he served as the President and CEO of Antios Therapeutics. It is anticipated that Mr. Mayes will be appointed to the Reunion Board of Directors to replace Ronan Levy, Reunion co-founder and current Chairman and CEO of Field Trip Health & Wellness Ltd., who will step down from Reunion’s Board in October 2022.
Board Change • Aug 25High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 7 experienced directors. No highly experienced directors. Independent Director Dieter Weinand is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Seeking Alpha • Aug 15Field Trip Health GAAP EPS of -C$0.09Field Trip Health press release (NASDAQ:FTRP): Q1 GAAP EPS of -C$0.09. As of June 30, 2022, the Company had unrestricted cash, cash equivalents and short-term investments of C$52.3 million, including C$4.1 million held at the Clinic Operations. Shares +4.42% AH.
Seeking Alpha • Jun 29Field Trip Health receives final court approval for clinics business spin-outPsychedelic therapies company Field Trip Health (NASDAQ:FTRP) said it has received final court approval for the spin-out of its clinics business to Field Trip Health & Wellness. The spin-out is to be executed by way of a plan of arrangement, with the closing subject to regulatory approvals. As part of the arrangement, each share of FTRP will be exchanged for one common share of FTRP, to be renamed Reunion Neuroscience on consummation of the arrangement, and ~0.86 common share of Field Trip Health & Wellness. The closing of the arrangement is set to occur on or around August. Field Trip Health & Wellness will list on the TSX Venture Exchange, subject to the exchange's approval. Additionally, Field Trip Health closed a private placement of subscription receipts of Field Trip Health & Wellness. The private placement, led by Bloom Burton Securities, involved an issue price of C$0.50 per receipt, with aggregate gross proceeds of C$2.1M. The net proceeds of the offering will be used for clinic operating expenses, working capital, arrangement expenses as well as for general corporate purposes. Source: Press Release
Board Change • Apr 27High number of new directorsIndependent Lead Director Barry Fishman was the last director to join the board, commencing their role in 2021.
Board Change • Mar 31High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 6 experienced directors. No highly experienced directors. CO-Founder, President & Director Hannan Fleiman is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Reported Earnings • Feb 17Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2022 results: CA$0.26 loss per share (down from CA$0.22 loss in 3Q 2021). Net loss: CA$15.0m (loss widened 81% from 3Q 2021). Revenue missed analyst estimates by 11%. Earnings per share (EPS) exceeded analyst estimates by 14%. Over the next year, revenue is forecast to grow 440%, compared to a 10.0% growth forecast for the industry in the US.
Reported Earnings • Nov 18Second quarter 2022 earnings released: CA$0.23 loss per share (vs CA$0.16 loss in 2Q 2021)Second quarter 2022 results: Net loss: CA$13.0m (loss widened 231% from 2Q 2021).
Board Change • Sep 14Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Member of Medical Advisory Board Matt Johnson was the last director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Sep 08Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Member of Medical Advisory Board Matt Johnson was the last director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 18First quarter 2022 earnings released: CA$0.22 loss per share (vs CA$1.69 loss in 1Q 2021)First quarter 2022 results: Net loss: CA$12.5m (loss widened 324% from 1Q 2021).
Board Change • Jul 30Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Member of Medical Advisory Board Matt Johnson was the last director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
